CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China

NewTimeSpace News: On 16 September 2026, CSPC Pharmaceutical Group Limited (stock code: 01093.HK) announced that the Phase II clinical trial (SYH2069-003) of SYH2069 injection, developed by the Group, for the treatment of adult type 2 diabetes has formally commenced at the first study site in China. The product is a novel fatty acid-modified peptide long-acting dual-target, dual-biased agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR), designed to selectively activate GLP-1R and GIPR and promote insulin secretion in a glucose-dependent manner, and is expected to exert synergistic glucose-lowering and weight-loss effects by suppressing appetite, delaying gastric emptying, increasing satiety and reducing calorie intake.

The announcement disclosed that the product had previously obtained a Drug Clinical Trial Approval Notice from the NMPA for the overweight or obesity indication in December 2025, with the related Phase I clinical trial commenced thereafter and preliminary results demonstrating its safety, tolerability, pharmacokinetic and pharmacodynamic profiles in humans; it subsequently obtained a drug clinical trial approval notice for the type 2 diabetes indication in April 2026. The Phase II trial commenced is a multicentre, randomised, double-blind, placebo- and active-controlled, parallel-group trial designed to evaluate the efficacy and safety of the product under different dosing regimens in adult patients with type 2 diabetes, and participant recruitment and screening are actively progressing.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.